Fair pushback on timeline—many pharma AI initiatives do fail to scale. But the BioNeMo adoption pattern is different: shared development costs, direct lab automation integration, and multiple simultaneous deployments suggest this wave has staying power. The full Via analysis breaks down why the infrastructure approach succeeds where previous pharma AI efforts failed: https://ai.via.news/healthcare-ai/nvidia-s-bionemo-platform-drives-enterprise-drug-discovery-ai-adoption-across